Fig. 2.

Multimodality imaging of spinal bone metastases in a pheochromocytoma/paraganglioma participant. The images of whole-body ⁶⁸Ga-DOTA(0)-Tyr(3)-octreotate ([⁶⁸Ga]DOTATATE; a anterior maximum intensity projection (MIP) and (b) fused sagittal PET/CT), ¹⁸F-fluoro-2-deoxy-d-glucose ([¹⁸F]FDG; c MIP and (d) fused sagittal PET/CT), T1-weighted sagittal MRI of the cervical (e), thoracic (f), and lumbar (g) spine, and contrast-enhanced CT (h sagittal) of a 25-year-old woman with germline pathogenic variant in a gene encoding for succinate dehydrogenase B subunit are shown. This figure shows superiority of [⁶⁸Ga]DOTATATE PET/CT in the detection of additional spinal bone metastases at C2, C5, C7, T1-2, T4-8, L2, and L5 compared to [¹⁸F]FDG PET/CT in detecting spinal bone metastases at T9 (arrow on fused sagittal image and not appreciated on MIP image) and L4 (not appreciated on MIP and fused sagittal images), and MRI spine at C6, T10-12, and L1 (arrows), respectively. The whole-body CT was read negative for any spinal bone metastases. This participant did not undergo whole-body MRI